Finanzen von Nurix Therapeutics Inc (NRIX)NRIXNurix Therapeutics Inc

Evaluating the bottom line, Nurix Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 83.12%, while the net margin is 81.69%. These profitability ratios, combined with a Return on Equity (ROE) of 43.99%, provide a clear picture of how effectively NRIX converts its operational activities into shareholder value.

In the context of the broader market, NRIX competes directly with industry leaders such as IRON and DYN. With a market capitalization of $2.59B, it holds a significant position in the sector. When comparing efficiency, NRIX's gross margin of 100.00% stands against IRON's N/A and DYN's N/A. Such benchmarking helps identify whether Nurix Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Nurix has demonstrated strong revenue growth, with Q3 2026 revenue reported at $673,064,000, a significant increase compared to previous quarters. The gross margin remains consistently high at 100%, indicating efficient cost management. The company has also shown a remarkable turnaround in net income, reporting $549,807,000 in Q3 2026 after several quarters of losses.